Background:Adiponectin is the most abundant adipokines that plays critical roles in the maintenance of energy homeostasis as well as inflammation regulation. The half-life of adiponectin is very short and the small-mo...Background:Adiponectin is the most abundant adipokines that plays critical roles in the maintenance of energy homeostasis as well as inflammation regulation. The half-life of adiponectin is very short and the small-molecule adiponectin receptor agonist has been synthesized recently. In the present study, the potential roles of AdipoRon, an adiponectin receptor agonist, in a mouse model of lipopolysaccharide (LPS)/D-galactosamine (D-Gal)-induced acute hepatitis was explored.Methods:BALB/c mice (n = 144, male) were divided into three sets. In set 1, 32 mice were randomized into four groups: the control group, the AdipoRon group, the LPS/D-Gal group, and the AdipoRon + LPS/D-Gal group. The mice in set 1 were sacrificed after LPS/D-Gal treatment, and the plasma samples were collected for detection of tumor necrosis factor-alpha (TNF-α). In set 2, the 32 mice were also divided into four groups similar to that of set 1. The mice were sacrificed 6 h after LPS/D-Gal injection and plasma samples and liver were collected. In set 3, 80 mice (divided into four groups, n = 20) were used for survival observation. The survival rate, plasma aminotransferases, histopathological damage were measured and compared between these four groups.Results:AdipoRon suppressed the elevation of plasma aminotransferases (from 2106.3 ± 781.9 to 286.8 ± 133.1 U/L for alanine aminotransferase, P < 0.01;from 566.5 ± 243.4 to 180.1 ± 153.3 U/L for aspartate aminotransferase, P < 0.01), attenuated histopathological damage and improved the survival rate (from 10% to 60%) in mice with LPS/D-Gal-induced acute hepatitis. Additionally, AdipoRon down-regulated the production of TNF-α (from 328.6 ± 121.2 to 213.4 ± 52.2 pg/mL, P < 0.01), inhibited the activation of caspase-3 (from 2.04-fold to 1.34-fold of the control), caspase-8 (from 2.03-fold to 1.31-fold of the control), and caspase-9 (from 2.14-fold to 1.43-fold of the control), and decreased the level of cleaved caspase-3 (0.28-fold to that of the LPS/D-Gal group). The number of terminal deoxynucleotidyl transferase-mediated nucleotide nick-end labeling-positive apoptotic hepatocytes in LPS/D-Gal-exposed mice also reduced.Conclusions:These data indicated that LPS/D-Gal-induced acute hepatitis was effectively attenuated by the adiponectin receptor agonist AdipoRon, implying that AdipoRon might become a new reagent for treatment of acute hepatitis.展开更多
脂联素受体激动剂(AdipoRon)是人工合成的与脂联素(ADPN)有相似作用的口服活性小分子,研究显示ADPN可调节成骨细胞生长和分化,但AdipoRon是否具有类似的功能目前鲜见报道。本试验主要研究AdipoRon对鸡成骨细胞的影响。从14日龄鸡胚额骨...脂联素受体激动剂(AdipoRon)是人工合成的与脂联素(ADPN)有相似作用的口服活性小分子,研究显示ADPN可调节成骨细胞生长和分化,但AdipoRon是否具有类似的功能目前鲜见报道。本试验主要研究AdipoRon对鸡成骨细胞的影响。从14日龄鸡胚额骨中分离获得成骨细胞,细胞培养第4日,分别添加100,200 mg/L AdipoRon处理成骨细胞,处理72 h后,MTT法检测细胞增殖活性,并进行碱性磷酸酶(ALP)染色。Real-time PCR检测脂联素受体1(AdipoR1)、脂联素受体2(AdipoR2)、成骨细胞成熟标志基因骨钙素(osteocalcin,OC)、Ⅰ型胶原α2链(alpa2 of type I collegen,COL1A2)、细胞凋亡相关基因Caspase-3、Bcl-2及Bax的基因表达量,计算Bcl-2与Bax基因表达量的比值。结果显示,100,200 mg/L AdipoRon处理后的成骨细胞正常形态消失,细胞数量减少,体积变小,细胞核明显固缩,细胞存活率极显著降低(P<0.01)。AdipoRon可增加成骨细胞中AdipoR1、AdipoR2、OC、Bcl-2、Bax和Caspase-3的表达量(P<0.05),并呈剂量依赖性,但对COL1A2和Bcl-2/Bax的表达无显著性影响。结果表明,100,200 mg/L AdipoRon均可促进鸡成骨细胞AdipoR1/2的表达,且能抑制成骨细胞的增殖,促进成骨细胞的成熟及凋亡。展开更多
The latest scientific knowledge has provided additional insights accountable for the worst prognosis for pancreatic ductal adenocarcinoma(PDAC).Among the causative factors,the aptitude to develop resistance towards ap...The latest scientific knowledge has provided additional insights accountable for the worst prognosis for pancreatic ductal adenocarcinoma(PDAC).Among the causative factors,the aptitude to develop resistance towards approved medications denotes the master key for understanding the lack of improvement in PDAC survival over the years.Even though several compounds have achieved encouraging results at preclinical stage,no new adjuvant agents have reached the bedside of PDAC patients lately.The adiponectin receptor agonist AdipoRon is emerging as a promising anticancer drug in different cancer models,particularly in PDAC.Building on the existing findings,we recently reinforced its candidacy in PDAC cells,proposing AdipoRon either as a suitable partner in gemcitabinebased treatment or as an effective drug in resistant cells.Crossing the current state-of-the-art,herein we provide a critical perspective on AdipoRon to figure out whether this receptor agonist can potentially be considered a future therapeutic choice in overcoming chemotherapy-induced resistance,expressly in PDAC.展开更多
文摘Background:Adiponectin is the most abundant adipokines that plays critical roles in the maintenance of energy homeostasis as well as inflammation regulation. The half-life of adiponectin is very short and the small-molecule adiponectin receptor agonist has been synthesized recently. In the present study, the potential roles of AdipoRon, an adiponectin receptor agonist, in a mouse model of lipopolysaccharide (LPS)/D-galactosamine (D-Gal)-induced acute hepatitis was explored.Methods:BALB/c mice (n = 144, male) were divided into three sets. In set 1, 32 mice were randomized into four groups: the control group, the AdipoRon group, the LPS/D-Gal group, and the AdipoRon + LPS/D-Gal group. The mice in set 1 were sacrificed after LPS/D-Gal treatment, and the plasma samples were collected for detection of tumor necrosis factor-alpha (TNF-α). In set 2, the 32 mice were also divided into four groups similar to that of set 1. The mice were sacrificed 6 h after LPS/D-Gal injection and plasma samples and liver were collected. In set 3, 80 mice (divided into four groups, n = 20) were used for survival observation. The survival rate, plasma aminotransferases, histopathological damage were measured and compared between these four groups.Results:AdipoRon suppressed the elevation of plasma aminotransferases (from 2106.3 ± 781.9 to 286.8 ± 133.1 U/L for alanine aminotransferase, P < 0.01;from 566.5 ± 243.4 to 180.1 ± 153.3 U/L for aspartate aminotransferase, P < 0.01), attenuated histopathological damage and improved the survival rate (from 10% to 60%) in mice with LPS/D-Gal-induced acute hepatitis. Additionally, AdipoRon down-regulated the production of TNF-α (from 328.6 ± 121.2 to 213.4 ± 52.2 pg/mL, P < 0.01), inhibited the activation of caspase-3 (from 2.04-fold to 1.34-fold of the control), caspase-8 (from 2.03-fold to 1.31-fold of the control), and caspase-9 (from 2.14-fold to 1.43-fold of the control), and decreased the level of cleaved caspase-3 (0.28-fold to that of the LPS/D-Gal group). The number of terminal deoxynucleotidyl transferase-mediated nucleotide nick-end labeling-positive apoptotic hepatocytes in LPS/D-Gal-exposed mice also reduced.Conclusions:These data indicated that LPS/D-Gal-induced acute hepatitis was effectively attenuated by the adiponectin receptor agonist AdipoRon, implying that AdipoRon might become a new reagent for treatment of acute hepatitis.
文摘脂联素受体激动剂(AdipoRon)是人工合成的与脂联素(ADPN)有相似作用的口服活性小分子,研究显示ADPN可调节成骨细胞生长和分化,但AdipoRon是否具有类似的功能目前鲜见报道。本试验主要研究AdipoRon对鸡成骨细胞的影响。从14日龄鸡胚额骨中分离获得成骨细胞,细胞培养第4日,分别添加100,200 mg/L AdipoRon处理成骨细胞,处理72 h后,MTT法检测细胞增殖活性,并进行碱性磷酸酶(ALP)染色。Real-time PCR检测脂联素受体1(AdipoR1)、脂联素受体2(AdipoR2)、成骨细胞成熟标志基因骨钙素(osteocalcin,OC)、Ⅰ型胶原α2链(alpa2 of type I collegen,COL1A2)、细胞凋亡相关基因Caspase-3、Bcl-2及Bax的基因表达量,计算Bcl-2与Bax基因表达量的比值。结果显示,100,200 mg/L AdipoRon处理后的成骨细胞正常形态消失,细胞数量减少,体积变小,细胞核明显固缩,细胞存活率极显著降低(P<0.01)。AdipoRon可增加成骨细胞中AdipoR1、AdipoR2、OC、Bcl-2、Bax和Caspase-3的表达量(P<0.05),并呈剂量依赖性,但对COL1A2和Bcl-2/Bax的表达无显著性影响。结果表明,100,200 mg/L AdipoRon均可促进鸡成骨细胞AdipoR1/2的表达,且能抑制成骨细胞的增殖,促进成骨细胞的成熟及凋亡。
文摘The latest scientific knowledge has provided additional insights accountable for the worst prognosis for pancreatic ductal adenocarcinoma(PDAC).Among the causative factors,the aptitude to develop resistance towards approved medications denotes the master key for understanding the lack of improvement in PDAC survival over the years.Even though several compounds have achieved encouraging results at preclinical stage,no new adjuvant agents have reached the bedside of PDAC patients lately.The adiponectin receptor agonist AdipoRon is emerging as a promising anticancer drug in different cancer models,particularly in PDAC.Building on the existing findings,we recently reinforced its candidacy in PDAC cells,proposing AdipoRon either as a suitable partner in gemcitabinebased treatment or as an effective drug in resistant cells.Crossing the current state-of-the-art,herein we provide a critical perspective on AdipoRon to figure out whether this receptor agonist can potentially be considered a future therapeutic choice in overcoming chemotherapy-induced resistance,expressly in PDAC.
